Page 58 - Read Online

Huang et al. J Transl Genet Genom 2021;5:240-9 https://dx.doi.org/10.20517/jtgg.2021.14 Page 248

Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121-31. DOI
PubMed
10. Chi KN, Agarwal N, Bjartell A, et al; TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J
Med 2019;381:13-24. DOI PubMed
11. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall
survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.
DOI PubMed
12. Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the
treatment of castration-resistant prostate cancer. Endocrinology 2010;151:3514-20. DOI PubMed
13. Chang KH, Li R, Kuri B, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell
2013;154:1074-84. DOI PubMed PMC
14. Naelitz BD, Sharifi N. Through the looking-glass: reevaluating DHEA metabolism through HSD3B1 genetics. Trends Endocrinol
Metab 2020;31:680-90. DOI PubMed PMC
15. Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation
therapy in men with prostate cancer. J Clin Oncol 2008;26:842-7. DOI PubMed
16. Wu G, Huang S, Nastiuk KL, et al. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer. Prostate
2015;75:777-82. DOI PubMed PMC
17. Hearn JWD, Abuali G, Reichard CA, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective,
multicohort study. Lancet Oncol 2016;17:1435-44. DOI PubMed
18. Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L. Independent validation of effect of HSD3B1 genotype
on response to androgen-deprivation therapy in prostate cancer. JAMA Oncol 2017;3:856-7. DOI PubMed PMC
19. Shiota M, Narita S, Akamatsu S, et al. Association of missense polymorphism in HSD3B1 with outcomes among men with prostate
cancer treated with androgen-deprivation therapy or abiraterone. JAMA Netw Open 2019;2:e190115. DOI PubMed
20. Hearn JWD, Xie W, Nakabayashi M, et al. Association of HSD3B1 genotype with response to androgen-deprivation therapy for
biochemical recurrence after radiotherapy for localized prostate cancer. JAMA Oncol 2018;4:558-62. DOI PubMed PMC
21. Hearn JWD, Sweeney CJ, Almassi N, et al. HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer.
JAMA Oncol 2020;6:e196496. DOI PubMed PMC
22. Han FF, Ren LL, Xuan LL, et al. HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer. Cancer Chemother
Pharmacol 2021;87:103-12. DOI PubMed
23. Chen WS, Feng EL, Aggarwal R, et al. Germline polymorphisms associated with impaired survival outcomes and somatic tumor
alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis 2020;23:316-23. DOI PubMed PMC
24. Stangl-Kremser J, Lemberger U, Hassler MR, et al. Prevalence and prognostic value of the polymorphic variant 1245A>C of HSD3B1
in castration-resistant prostate cancer. Clin Genitourin Cancer 2019;17:389-94. DOI PubMed
25. Li Z, Bishop AC, Alyamani M, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature
2015;523:347-51. DOI PubMed PMC
26. Lee BH. Commentary on: "Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy." Li Z, Alyamani M,
Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N. Nature 2016;533:547-51. Urol Oncol
2017;35:576. DOI PubMed
27. Alyamani M, Emamekhoo H, Park S, et al. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate
cancer. J Clin Invest 2018;128:3333-40. DOI PubMed PMC
28. Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen
receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012;72:2176-82. DOI PubMed
PMC
29. Almassi N, Reichard C, Li J, et al. HSD3B1 and Response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer.
JAMA Oncol 2018;4:554-7. DOI PubMed PMC
30. Hahn AW, Gill DM, Nussenzveig RH, et al. Germline variant in HSD3B1 (1245 A > C) and response to abiraterone acetate plus
prednisone in men with new-onset metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16:288-92. DOI
PubMed
31. Khalaf DJ, Aragón IM, Annala M, et al; PROREPAIR-B investigators. HSD3B1 (1245A>C) germline variant and clinical outcomes in
metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Ann Oncol 2020;31:1186-97. DOI PubMed
32. Lu C, Terbuch A, Dolling D, et al. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic
castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. Ann Oncol 2020;31:1178-85.
DOI PubMed
33. Shiota M, Akamatsu S, Narita S, et al. The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment
failure with abiraterone for castration-resistant prostate cancer. Pharmacogenomics J 2021. DOI PubMed
34. Fizazi K, Tran N, Fein L, et al; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate
cancer. N Engl J Med 2017;377:352-60. DOI PubMed
35. Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-
sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol
2019;20:686-700. DOI PubMed